



IN THE UNITED STATES PATENT & TRADEMARK OFFICE

IN RE APPLICATION OF:
SLAGA, et al.

SERIAL NO. 10/004,105

FILED: 12/04/01

§
§
§
§
§
§
§

EXAMINER: SPIVACK, P.

GROUP ART UNIT: 1614

TECH CENTER 1600/2900

FEB 26 2003

RECEIVED

INP
7-A
VCS
3-4-23

TITLE: THE USE OF EUGENOL, ALONE, AND IN COMBINATION WITH OTHER
CHEMOPREVENTATIVE AGENTS AS PROPHYLAXIS FOR CANCERS

COMMISSIONER OF PATENTS
AND TRADEMARKS
WASHINGTON, D.C. 20231

AMENDMENTS

In the Specification:

Please amend the title of the application to read as follows:

A 1

THE USE OF 2ME AND EUGENOL, ALONE OR IN COMBINATION, IN THE

TREATMENT AND PREVENTION OF NON-CANCEROUS ENLARGED PROSTATE

Please add the following Brief Description of the Invention:

BRIEF DESCRIPTION OF THE DRAWINGS

A 2
Fig. 1 is a graphical depiction of data establishing eugenol inhibits the growth of LNCaP cells significantly – a concentration of approximately .075 mM being necessary to see 50% inhibition of growth of LNCaP cells – whereas a concentration of more than 2mM was necessary to see a similar effect in DU145 cells.

Fig. 2 is a graphical depiction of data establishing 2ME inhibits the growth of LNCaP